Reza Hosseini Ghomi, MD, Chief Medical Officer, BrainCheck, discusses the recent approval of aducanumab for the treatment of Alzheimer’s disease or a specific dementia diagnosis. Because of the need for specific diagnoses to receive this drug, Dr Ghomi notes that a backlog may develop of patients needing biomarker-confirmed diagnoses. Earlier identification of cognitive impairment and subsequent specific diagnosis will facilitate earlier treatment and limit the need for additional testing.